Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old.
• People whose pancreatic cancer has been confirmed through a tissue or cell sample test (biopsy or similar).
• People whose cancer is classified as "borderline resectable," meaning it may be possible to remove with surgery but is in a difficult location.
• People who have at least one tumour that can be measured on a scan, where the tumour is no larger than 6 cm, is at least 0.5 cm away from the lining of the digestive tract, shows no clear signs of growing into nearby tissue, and has no obvious spread to nearby lymph nodes.
• People who have not previously received any treatment for their pancreatic cancer.
• People who are generally well enough to carry out light activity and care for themselves (a measure doctors use called ECOG performance status 0–1).
• People with a life expectancy of at least 3 months.
• People whose blood counts meet specific healthy levels, including white blood cells, neutrophils, platelets, and haemoglobin (confirm with trial site for exact values).
• People whose liver function test results are within an acceptable range based on standard laboratory reference levels.
• People whose kidney function is within an acceptable range, based on either a blood test or a calculated kidney function score.
• People of reproductive potential who are willing to use at least one medically accepted form of contraception during treatment and for 180 days after treatment ends; women must have a negative pregnancy blood test before the first dose and must not be breastfeeding.
• People who understand what the study involves and who (or whose legal representative) are willing to sign a consent form to participate.

Who may not be able to join:

• People who have had another type of cancer in the past 5 years, except for certain fully treated skin cancers (such as basal cell carcinoma or treated in situ cancer).
• People who have had major surgery within the past 28 days.
• People who have previously received certain immune-based cancer treatments, including drugs that target PD-1, PD-L1, PD-L2, or CTLA-4.
• People whose cancer has already spread to distant parts of the body in a way that cannot be surgically removed.
• People with an active, uncontrolled infection (bacterial, viral, or fungal) that has not improved with appropriate treatment.
• People with known active HIV infection, untreated active hepatitis B (with certain detectable virus levels), or active hepatitis C infection.
• People with serious uncontrolled conditions affecting the heart or other body systems, such as unstable angina, recent heart attack, heart failure, serious irregular heartbeat, or severe heart lining disease.
• People with serious digestive tract problems, including active bleeding, significant blockage, or significant diarrhoea (above a certain severity level — confirm with trial site).
• People whose test results or clinical assessment show any reason why chemotherapy, radiotherapy, or surgery would not be safe for them.
• Women who are pregnant or breastfeeding, or women who could become pregnant but are not willing to use appropriate contraception during the trial.

Important: Always verify eligibility with the trial site directly before applying.